Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations

Benigno C. Valdez(The University of Texas MD Anderson Cancer Center), Börje S. Andersson(The University of Texas MD Anderson Cancer Center)
International Journal of Molecular Sciences
August 26, 2024
10.3390/ijms25179241
Cited by 8

Related Papers

Romidepsin targets multiple survival signaling pathways in malignant T cells
|Blood Cancer Journal|2015|72
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
|Experimental Hematology|2012|45
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells
|Oncotarget|2017|45
Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
|Blood Cancer Journal|2014|19
Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy
|Oncotarget|2016|19